Literature DB >> 32852377

Micropulse Cyclophotocoagulation: A Multicenter Study of Efficacy, Safety, and Factors Associated With Increased Risk of Complications.

Sunita Radhakrishnan1,2, Juan Wan2, Brendan Tran3, Andy Thai3, Jonathan Hernandez-Siman4, Kaddie Chen5, Ngoc Nguyen3, Terri-Diann Pickering1, H George Tanaka4,6, Marc Lieberman6, Patricia Wong6, Andrew G Iwach1,2.   

Abstract

PRéCIS:: Micropulse cyclophotocoagulation (MPCP) lowered intraocular pressure (IOP) in the short-term but nearly half required additional intervention. Mydriasis was the most common complication (11%); 15% lost ≥3 Snellen lines of acuity; 11% had persistent complications at last follow-up.
PURPOSE: The purpose of this study was to evaluate the efficacy and complications of MPCP in a large series of patients with all stages of glaucoma.
DESIGN: Multicenter, retrospective chart review of patients from 3 clinical sites. PARTICIPANTS: One hundred sixty-seven eyes of 143 patients.
METHODS: MPCP was performed with 2000 mW energy, 31.3% duty cycle and 2 to 4 180-degree applications of 80 seconds duration each per treatment. The procedure was considered a failure if any of the following occurred: additional IOP lowering intervention, <20% IOP reduction from baseline at the last follow-up (with or without medication), or severe complications.
RESULTS: Mean age was 71 years, 53% were female, and 53% were Asian. 60% of eyes had POAG, 63% were pseudophakic, 38% had prior glaucoma surgery, and 51% had Snellen visual acuity (VA) of 20/40 or better. Mean follow-up time was 11.9±7.8 months. Mean IOP was 21.9±8.4 mm Hg before intervention, and 17.4±7.2 mm Hg at last follow-up (P<0.0001). There was no change in mean logMAR VA (P=0.0565) but 15% lost ≥3 Snellen lines of VA. The success rate was 36.5% (61/167 eyes) at last follow-up. The probability of survival by Kaplan-Meier analysis was 82%, 71%, and 57% at 3, 6, and 12 months after the procedure, respectively. The reasons for failure were additional intervention in 47%, inadequate IOP reduction in 14%, and severe complication in 1.8%. In a multivariable Cox proportional hazard model, female sex was associated with a 56% decrease in failure rate compared with males (P<0.0001), while a unit increase in baseline IOP corresponded with a 5.7% increase in failure rate (P<0.0001). If repeat MPCP was allowed then success rate increased to 58%. There were no complications in 73% (122/167) but 11% (18/167) had persistent complications at the last follow-up and half of these 18 eyes had decrease in VA of 1 to 6 Snellen lines. Asian race (odds ratio 13.5, P=0.0131) and phakic status (odds ratio 3.1, P=0.0386) were associated with higher odds of developing mydriasis, which was the most common complication.
CONCLUSIONS: MPCP lowered IOP in the short-term but nearly half required additional IOP lowering intervention. Potential complications should be discussed in detail especially when the procedure is being considered for those with good VA and early stage disease.

Entities:  

Year:  2020        PMID: 32852377     DOI: 10.1097/IJG.0000000000001644

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  7 in total

1.  The Histopathology of Two Eyes Enucleated after Continuous Transscleral and Micropulse Transscleral Cyclophotocoagulation for Refractory Secondary Glaucoma.

Authors:  Imani M Williams; Vamsee K Neerukonda; Anna M Stagner
Journal:  Ocul Oncol Pathol       Date:  2022-01-24

Review 2.  Clinical outcomes of slow-coagulation continuous-wave transscleral cyclophotocoagulation laser for treatment of glaucoma.

Authors:  Mohamed M Khodeiry; Xiangxiang Liu; Richard K Lee
Journal:  Curr Opin Ophthalmol       Date:  2022-02-23       Impact factor: 4.299

3.  Evidence-Based Consensus Guidelines Series for MicroPulse Transscleral Laser Therapy: Dosimetry and Patient Selection.

Authors:  Tomas M Grippo; Ronald M P C de Crom; Michael Giovingo; Marc Töteberg-Harms; Brian A Francis; Brian Jerkins; Jacob W Brubaker; Nathan Radcliffe; Jella An; Robert Noecker
Journal:  Clin Ophthalmol       Date:  2022-06-07

4.  MicroPulse Transscleral Laser Therapy Demonstrates Similar Efficacy with a Superior and More Favorable Safety Profile Compared to Continuous-Wave Transscleral Cyclophotocoagulation.

Authors:  Enrico Bernardi; Marc Töteberg-Harms
Journal:  J Ophthalmol       Date:  2022-02-08       Impact factor: 1.909

5.  Medium-term Outcomes of Micropulse Transscleral Cyclophotocoagulation in Refractory Glaucoma.

Authors:  Inigo Tejada Valle; Sara Pose Bazarra; Miguel Ferreira Taboas; Sara Rubio Cid; Maria Dolores Alvarez Diaz
Journal:  J Curr Glaucoma Pract       Date:  2022 May-Aug

6.  Ciliochoroidal effusion and its association with the outcomes of micropulse transscleral laser therapy in glaucoma patients: a pilot study.

Authors:  Sunee Chansangpetch; Natnaree Taechajongjintana; Kitiya Ratanawongphaibul; Rath Itthipanichpong; Anita Manassakorn; Visanee Tantisevi; Prin Rojanapongpun; Shan C Lin
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

7.  Topical Anesthesia Offers Sufficient Pain Control for MicroPulse Transscleral Laser Therapy for Glaucoma.

Authors:  Belgin Vasella; Marc Töteberg-Harms
Journal:  J Ophthalmol       Date:  2022-09-21       Impact factor: 1.974

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.